These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23178734)

  • 1. Weighted log-rank statistic to compare shared-path adaptive treatment strategies.
    Kidwell KM; Wahed AS
    Biostatistics; 2013 Apr; 14(2):299-312. PubMed ID: 23178734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sample size for two-stage studies with maintenance therapy.
    Feng W; Wahed AS
    Stat Med; 2009 Jul; 28(15):2028-41. PubMed ID: 19382105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Up-front versus sequential randomizations for inference on adaptive treatment strategies.
    Ko JH; Wahed AS
    Stat Med; 2012 Apr; 31(9):812-30. PubMed ID: 22362642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cox regression methods for two-stage randomization designs.
    Lokhnygina Y; Helterbrand JD
    Biometrics; 2007 Jun; 63(2):422-8. PubMed ID: 17425633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A sample size formula for the supremum log-rank statistic.
    Eng KH; Kosorok MR
    Biometrics; 2005 Mar; 61(1):86-91. PubMed ID: 15737081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal response-adaptive randomized designs for multi-armed survival trials.
    Sverdlov O; Tymofyeyev Y; Wong WK
    Stat Med; 2011 Oct; 30(24):2890-910. PubMed ID: 21823146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Test homogeneity of odds ratio in a randomized clinical trial with noncompliance.
    Lui KJ; Chang KC
    J Biopharm Stat; 2009 Sep; 19(5):916-32. PubMed ID: 20183452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous use of weighted logrank and standardized Kaplan-Meier statistics.
    Yang P; Fleming TR
    J Biopharm Stat; 2006; 16(2):241-52. PubMed ID: 16584070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of factorial survival experiments.
    Slud EV
    Biometrics; 1994 Mar; 50(1):25-38. PubMed ID: 8086609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
    Horiguchi M; Hassett MJ; Uno H
    Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Group sequential monitoring based on the weighted log-rank test statistic with the Fleming-Harrington class of weights in cancer vaccine studies.
    Hasegawa T
    Pharm Stat; 2016 Sep; 15(5):412-9. PubMed ID: 27353855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Permutation test following covariate-adaptive randomization in randomized controlled trials.
    Hasegawa T; Tango T
    J Biopharm Stat; 2009; 19(1):106-19. PubMed ID: 19127470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of sequentially randomized trials for testing adaptive treatment strategies.
    Ogbagaber SB; Karp J; Wahed AS
    Stat Med; 2016 Mar; 35(6):840-58. PubMed ID: 26412033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conditional Monte Carlo randomization tests for regression models.
    Parhat P; Rosenberger WF; Diao G
    Stat Med; 2014 Aug; 33(18):3078-88. PubMed ID: 24648378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Policy versus practice: comparison of prescribing therapy and durable medical equipment in medical and educational settings.
    Sneed RC; May WL; Stencel C
    Pediatrics; 2004 Nov; 114(5):e612-25. PubMed ID: 15520092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive trial design: a general methodology for censored time to event data.
    Jahn-Eimermacher A; Ingel K
    Contemp Clin Trials; 2009 Mar; 30(2):171-7. PubMed ID: 19130902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjusting for observational secondary treatments in estimating the effects of randomized treatments.
    Zhang M; Wang Y
    Biostatistics; 2013 Jul; 14(3):491-501. PubMed ID: 23349243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of randomization on the analysis of clinical trials.
    Rosenkranz GK
    Stat Med; 2011 Dec; 30(30):3475-87. PubMed ID: 21953285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urn models for response-adaptive randomized designs: a simulation study based on a non-adaptive randomized trial.
    Ghiglietti A; Scarale MG; Miceli R; Ieva F; Mariani L; Gavazzi C; Paganoni AM; Edefonti V
    J Biopharm Stat; 2018; 28(6):1203-1215. PubMed ID: 29565749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A likelihood ratio test for cancer screening trials.
    Self SG; Etzioni R
    Biometrics; 1995 Mar; 51(1):44-50. PubMed ID: 7766795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.